Management of conduction disorders after transcatheter aortic valve implantation: results of the EHRA survey.


Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
21 07 2022
Historique:
received: 01 02 2022
accepted: 16 02 2022
pubmed: 30 3 2022
medline: 26 7 2022
entrez: 29 3 2022
Statut: ppublish

Résumé

Conduction disorders such as left bundle branch block (LBBB) are common after transcatheter aortic valve implantation (TAVI). Consensus regarding a reasonable strategy to manage conduction disturbances after TAVI has been elusive. The European Heart Rhythm Association (EHRA) conducted a survey to capture contemporary clinical practice for conduction disorders after TAVI. A 25-item online questionnaire was developed and distributed among the EHRA electrophysiology (EP) research network centres. Of 117 respondents, 44% were affiliated with university hospitals. A standardized management protocol for advanced conduction disorders such as LBBB or atrioventricular block (AVB) after TAVI was available in 63% of participating centres. Telemetry after TAVI was chosen as the most frequent management strategy for patients with new-onset or pre-existing LBBB (79% and 70%, respectively). Duration of telemetry in patients with new-onset LBBB varied, with a 48-h period being the most frequently chosen, but almost half monitoring continued for at least 72 h. Similarly, in patients undergoing EP study due to new-onset LBBB, the HV interval cut-off point leading to pacemaker implantation was heterogeneous among European centres, although an HV >75 ms threshold was the most common. Conduction system pacing was chosen as a preferred approach by 3.7% of respondents for patients with LBBB and normal left ventricular ejection fraction (LVEF), and by 5.6% for patients with LBBB and reduced LVEF. This survey suggests some heterogenity in the management of conduction disorders after TAVI across European centres. The risk stratification strategies vary substantially. Conduction system pacing in patients with LBBB after TAVI is still underused.

Identifiants

pubmed: 35348646
pii: 6554408
doi: 10.1093/europace/euac027
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1179-1185

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2022. For permissions, please email: journals.permissions@oup.com.

Auteurs

Patrick Badertscher (P)

Department of Cardiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Sven Knecht (S)

Department of Cardiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Ivan Zeljković (I)

Department of Cardiology, University Hospital Sestre Milosrdnice, 10000 Zagreb, Croatia.

Christian Sticherling (C)

Department of Cardiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Carlo de Asmundis (C)

Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, Brussels, Belgium.

Giulio Conte (G)

Division of Cardiology, Cardiocentro Ticino Institute, Lugano, Switzerland.
Università della Svizzera Italiana Lugano, Lugano, Switzerland.

Sérgio Barra (S)

Cardiology Department, Hospital da Luz Arrabida, V.N. Gaia, Portugal.
Cardiology Department, Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.

Kosiuk Jedrzej (K)

Department of Rhythmology, Hellos Clinic Köthen, Köthen, Germany.

Michael Kühne (M)

Department of Cardiology, University Hospital Basel, Petersgraben 4, 4031 Basel, Switzerland.
Cardiovascular Research Institute Basel, University Hospital Basel, Basel, Switzerland.

Serge Boveda (S)

Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, Brussels, Belgium.
INSERM Unit 970, Paris, France.
Heart Rhythm Management Department, Clinique Pasteur, 45 Avenue de Lombez, 31076 Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH